SynOx Therapeutics is a clinical-stage company focused on developing emactuzumab, a differentiated, next-generation monoclonal antibody targeting CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies
SynOx Therapeutics is a clinical-stage company focused on developing emactuzumab, a differentiated, next-generation monoclonal antibody targeting CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies.